Ketamine/Esketamine in the Treatment of Serious and Persistent Depression: Practical Considerations
Image For Activity Cover
Availability
On-Demand
Expires on Apr 16, 2026
Credit Offered
1 CME Credit
1 NCPD Credit
1 COP Credit

This presentation briefly reviews the science and pharmacology that led to the development of ketamine and esketamine as a treatment for neuropsychiatric disorders. It specifically focuses on major issues to be contemplated when considering recommending treatment with ketamine or esketamine to treat severe and persistent major depressive disorder. And, critically reviews the existing data from a wide range of clinical trials and attempt to incorporate this data into clinical decision making processes.

Learning Objectives

  • Summarize the history of the discovery of ketamine’s rapid onset of antidepressant effects, and the early clinical evidence of ketamine’s antidepressant properties
  • Outline the key clinically relevant questions related to the use of ketamine
  • Evaluate the results from a series of studies conducted over the past couple of years addressing the critically import questions related to ketamine’s use in the clinic and the development of rapidly acting antidepressants

Target Audience

Nurse/Nurse Practitioner, Physician (non-psychiatrist), Physician Assistant, Psychiatrist, Pharmacist

Instructional Level

Intermediate

Estimated Time to Complete

Estimated Duration: 1.0 hour
Program Start Date: April 16, 2020
Program End Date: April 16, 2026

Ongoing Interdisciplinary Discussion Board

If there are any topics covered in this webinar that you would like to discuss with colleagues in the mental health field, post a question or comment on SMI Adviser’s Webinar Roundtable Topics discussion board (https://smiadviser.org/discussion). This is an easy way to network and share ideas with other clinicians who participate in this webinar.

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit™, nursing continuing professional development pharmacology contact hours (NCPD, formerly CNE), or a certificate of participation may do so by completing all sections of the course, including the evaluation. A multiple choice quiz is provided based on the content. A passing score of 75% must be achieved. Retakes are available for the test. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians), NCPD certificate (nurses), or certificate of participation (other professions) showing the completion date and hours earned.

Continuing Education Credit

Physicians

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 The APA designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses/Nurse Practitioners

The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Faculty and Planner Disclosures

Faculty

  • Gerard Sanacora, MD, PhD, Associate Professor and Director of the Yale Depression Research Program, Yale University. Disclosures Stock: Biohaven Pharmaceuticals; Consultant: Allergan, Alkermes, AstraZeneca, Avanier, Axsome Therapeutics, Pharmaceuticals, Biohaven Pharmaceuticals, BristolMyers Squibb, Clexio Biosciences, EMA Wellness, Epiodyne, Intra-Cellular Therapies, Janssen, Merck & Co., Naurex, Navitor, NeruoRx, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, and Vistagen Therapeutics; Grant/Research: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Hoffman La-Roche, Merck, Naurex, and Servier.

Planners

  • Teri Brister, PhD, LPC, National Alliance on Mental Illness. Reports no financial relationships with commercial interests.
  • Tristan Gorrindo, MD, American Psychiatric Association. Reports no financial relationships with commercial interests.
  • Donna Rolin, PhD, APRN, University of Texas at Austin. Reports no financial relationships with commercial interests. 
Reviewers
  • Teri Brister, PhD, LPC, National Alliance on Mental Illness. Reports no financial relationships with commercial interests. (Reviewed on 4/10/2023)
  • John Torous, MD, Beth Israel Deaconess Medical Center. Reports no financial relationships with commercial interests. (Reviewed on 4/10/2023)
  • Donna Rolin, PhD, APRN, University of Texas at Austin. Reports no financial relationships with commercial interests. (Reviewed on 4/10/2023)

Accessibility for Participants with Disabilities

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.

Technical Requirements

This internet-based CME activity is best experienced using any of the following:

  • The latest and 2nd latest public versions of Google Chrome, Mozilla Firefox, or Safari
  • Internet Explorer 11+

This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat Reader, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:

  • Browser: Google Chrome (latest and 2nd latest version), Safari (latest and 2nd latest version), Internet Explorer 11.0+, Firefox (latest and 2nd latest version), or Microsoft Edge (latest and 2nd latest version)
  • Operating System: Windows versions 8.1+, Mac OS X 10.5 (Leopard) +, Android (latest and 2nd latest version), or iOS/iPad OS (latest and 2nd latest version)
  • Internet Connection: 1 Mbps or higher

Minimum Requirements:

  • Windows PC: Windows 8.1 or higher; 1 GB (for 32-bit)/2 GB (for 64-bit) or higher RAM; Microsoft DirectX 9 graphics device with WDDM driver; audio playback with speakers for programs with video content
  • Macintosh: Mac OS X 10.5 or higher with latest updates installed; Intel, PowerPC G5, or PowerPC G4 (867MHz or faster) processor; 512 MB or higher RAM; audio playback with speakers for programs with video content

For assistance: Contact educme@psych.org for questions about this activity | Contact SMIAdviserHelp@psych.org for technical assistance

Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
Powered By